IGM Biosciences/IGMS

$9.09

-1.62%
-
1D1W1MYTD1YMAX

About IGM Biosciences

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Ticker

IGMS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Fred Schwarzer

Employees

216

Headquarters

Mountain view, United States
Website
igmbio.com

IGM Biosciences Metrics

BasicAdvanced
$545M
Market cap
-
P/E ratio
-$4.31
EPS
0.24
Beta
-
Dividend rate
$545M
0.2362
$17.70
$3.81
309K
7.982
-56.49%
-118.26%
-62.57%
259.087
3.378
3.382
32.31%
16.63%

What the Analysts think about IGM Biosciences

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 9 analysts.
148.18% upside
High $48.00
Low $12.00
$9.09
Current price
$22.56
Average price target

IGM Biosciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-12,450% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$400K
-33.33%
Net income
-$50M
-17.82%
Profit margin
-12,450%
23.27%

IGM Biosciences Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.16%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.43
-$1.04
-$1.01
-$0.83
-
Expected
-$1.43
-$1.21
-$1.03
-$0.83
-$0.04
Surprise
-0.28%
-14.26%
-2.19%
-0.16%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for IGM Biosciences stock?

IGM Biosciences (IGMS) has a market cap of $545M as of May 30, 2024.

What is the P/E ratio for IGM Biosciences stock?

The price to earnings (P/E) ratio for IGM Biosciences (IGMS) stock is 0 as of May 30, 2024.

Does IGM Biosciences stock pay dividends?

No, IGM Biosciences (IGMS) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next IGM Biosciences dividend payment date?

IGM Biosciences (IGMS) stock does not pay dividends to its shareholders.

What is the beta indicator for IGM Biosciences?

IGM Biosciences (IGMS) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the IGM Biosciences stock price target?

The target price for IGM Biosciences (IGMS) stock is $22.56, which is 148.18% above the current price of $9.09. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell IGM Biosciences stock

Buy or sell IGM Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing